Advertisement

Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter

  • Hyo Eun Park
  • Heesun Lee
  • Su-Yeon Choi
  • Min-Sun Kwak
  • Jong In Yang
  • Jeong Yoon Yim
  • Goh Eun Chung
Original Article—Liver, Pancreas, and Biliary Tract
  • 43 Downloads

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) plays a significant role in coronary atherosclerosis, independent of shared metabolic risk factors. The measurement of the controlled attenuation parameter (CAP) has shown to allow early and noninvasive detection of NAFLD at subclinical stage. We evaluated the significance of CAP-defined NAFLD in association with the presence of any type of coronary plaques and different plaque compositions.

Methods

We conducted a retrospective cohort of apparently healthy subjects who had liver Fibroscan and coronary computed tomography during health screening exams.

Results

A greater number of subjects with CAP-defined NAFLD was found in group with coronary plaques (61.3% vs. 73.5%, p = 0.005 without vs. with any type of plaque). From multivariate regression model, CAP ≥ 222 dB/m was an independent and significant parameter associated with the presence of coronary plaques, after adjusting possible confounders (OR 1.624, 95% 1.047–2.518, p = 0.030). Interestingly, CAP ≥ 222 dB/m was significantly associated with non-calcified plaque (adjusted OR 3.528, 95% CI 1.463–8.511, p = 0.005), whereas it was not significant in calcified plaques (p = 0.171).

Conclusion

CAP-defined NAFLD is independently associated with coronary plaques, especially non-calcified plaques. The association between NAFLD and non-calcified plaques suggests that particular attention should be given to the subjects with NAFLD for primary prevention.

Keywords

Coronary plaque Controlled attenuation parameter NAFLD FibroScan 

Notes

Acknowledgements

We thank Boram Park for her contribution to this work, especially with the statistical analysis of the study.

Author contributions

HEP conceived the idea, determined the study design, collected the data, drafted and revised the manuscript. HL collected the data, performed the statistical analysis and revised the manuscript. S-YC collected the data, performed the statistical analysis and revised the manuscript. M-SK determined the study design, collected the data and drafted the manuscript. JIY collected the data and revised the manuscript. JYY collected the data and revised the manuscript. GEC determined the study design, collected the data, performed the statistical analysis and drafted the manuscript. All authors have read and approved the final draft of the manuscript.

Funding

There is nothing to declare.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

535_2018_1516_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 16 kb)

References

  1. 1.
    Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947–53.CrossRefGoogle Scholar
  2. 2.
    Park HE, Kwak MS, Kim D, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study. J Clin Endocrinol Metab. 2016;101:3134–43.CrossRefGoogle Scholar
  3. 3.
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.CrossRefGoogle Scholar
  4. 4.
    Chung GE, Choi SY, Kim D, et al. Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index. Medicine (Baltimore). 2015;94:e654.CrossRefGoogle Scholar
  5. 5.
    Choi SY, Kim D, Kim HJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol. 2009;104:1953–60.CrossRefGoogle Scholar
  6. 6.
    Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022–30.CrossRefGoogle Scholar
  7. 7.
    Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–35.CrossRefGoogle Scholar
  8. 8.
    Recio E, Cifuentes C, Macias J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25:905–11.CrossRefGoogle Scholar
  9. 9.
    Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–10.CrossRefGoogle Scholar
  10. 10.
    de Ledinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–8.CrossRefGoogle Scholar
  11. 11.
    You SC, Kim KJ, Kim SU, et al. Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. J Gastroenterol Hepatol. 2015;30:1536–42.CrossRefGoogle Scholar
  12. 12.
    Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003;108:1772–8.CrossRefGoogle Scholar
  13. 13.
    van Velzen JE, de Graaf FR, Jukema JW, et al. Comparison of the relation between the calcium score and plaque characteristics in patients with acute coronary syndrome versus patients with stable coronary artery disease, assessed by computed tomography angiography and virtual histology intravascular ultrasound. Am J Cardiol. 2011;108:658–64.CrossRefGoogle Scholar
  14. 14.
    Hausleiter J, Meyer T, Hadamitzky M, et al. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. J Am Coll Cardiol. 2006;48:312–8.CrossRefGoogle Scholar
  15. 15.
    Kang MK, Kang BH, Kim JH. Nonalcoholic fatty liver disease is associated with the presence and morphology of subclinical coronary atherosclerosis. Yonsei Med J. 2015;56:1288–95.CrossRefGoogle Scholar
  16. 16.
    Osawa K, Miyoshi T, Yamauchi K, et al. Nonalcoholic hepatic steatosis is a strong predictor of high-risk coronary-artery plaques as determined by multidetector CT. PLoS One. 2015;10:e0131138.CrossRefGoogle Scholar
  17. 17.
    Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.CrossRefGoogle Scholar
  18. 18.
    Chung GE, Kim D, Kwak MS, et al. The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. Clin Mol Hepatol. 2016;22:146–51.CrossRefGoogle Scholar
  19. 19.
    Choi SY, Kim D, Oh BH, et al. General and abdominal obesity and abdominal visceral fat accumulation associated with coronary artery calcification in Korean men. Atherosclerosis. 2010;213:273–8.CrossRefGoogle Scholar
  20. 20.
    Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–13.CrossRefGoogle Scholar
  21. 21.
    Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–91.CrossRefGoogle Scholar
  22. 22.
    Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359–68.CrossRefGoogle Scholar
  23. 23.
    Kwak MS, Chung GE, Yang JI, et al. Clinical implications of controlled attenuation parameter in a health check-up cohort. Liver Int. 2017;38:915–23.CrossRefGoogle Scholar
  24. 24.
    Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation. 2004;109:14–7.CrossRefGoogle Scholar
  25. 25.
    Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.CrossRefGoogle Scholar
  26. 26.
    Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.CrossRefGoogle Scholar
  27. 27.
    Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–6.CrossRefGoogle Scholar
  28. 28.
    McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–9.CrossRefGoogle Scholar
  29. 29.
    Kim JK, Lee KS, Choi JR, et al. Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees. Gut Liver. 2015;9:405–10.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Ferraioli G, Tinelli C, Lissandrin R, et al. Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study. Eur J Gastroenterol Hepatol. 2015;27:305–12.CrossRefGoogle Scholar
  31. 31.
    Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut. 2011;60:1721–7.CrossRefGoogle Scholar
  32. 32.
    Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50.CrossRefGoogle Scholar
  33. 33.
    Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27–38.CrossRefGoogle Scholar
  34. 34.
    Mellinger JL, Pencina KM, Massaro JM, et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J Hepatol. 2015;63:470–6.CrossRefGoogle Scholar
  35. 35.
    Akabame S, Hamaguchi M, Tomiyasu K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 2008;72:618–25.CrossRefGoogle Scholar
  36. 36.
    Assy N, Djibre A, Farah R, et al. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254:393–400.CrossRefGoogle Scholar
  37. 37.
    Puchner SB, Lu MT, Mayrhofer T, et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015;274:693–701.CrossRefGoogle Scholar
  38. 38.
    Papatheodoridis GV, Chrysanthos N, Cholongitas E, et al. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol. 2009;51:931–8.CrossRefGoogle Scholar
  39. 39.
    Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin Thromb Hemost. 2013;39:214–28.CrossRefGoogle Scholar
  40. 40.
    Targher G, Bertolini L, Scala L, et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22:1354–8.CrossRefGoogle Scholar
  41. 41.
    Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol. 2006;45:879–81 (author reply 881–872).CrossRefGoogle Scholar
  42. 42.
    Yener S, Akarsu M, Demir T, et al. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis. J Endocrinol Investig. 2007;30:810–9.CrossRefGoogle Scholar
  43. 43.
    Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–97.CrossRefGoogle Scholar
  44. 44.
    Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–9.CrossRefGoogle Scholar
  45. 45.
    Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105:2019–23.CrossRefGoogle Scholar
  46. 46.
    Norja S, Nuutila L, Karhunen PJ, et al. C-reactive protein in vulnerable coronary plaques. J Clin Pathol. 2007;60:545–8.CrossRefGoogle Scholar
  47. 47.
    Kubo T, Matsuo Y, Hayashi Y, et al. High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: a virtual histology intravascular ultrasound study. Coron Artery Dis. 2009;20:531–5.CrossRefGoogle Scholar
  48. 48.
    Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348–59.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  1. 1.Division of Cardiology, Department of Internal MedicineHealthcare System Gangnam Center, Seoul National University HospitalSeoulKorea
  2. 2.Division of Gastroenterology, Department of Internal MedicineHealthcare System Gangnam Center, Seoul National University HospitalSeoulKorea

Personalised recommendations